Leucine rich repeat kinase 2
Synonyms: DKFZp434H2111, FLJ45829, RIPK7, ROCO2, PARK8
LRRK2 is one of the most promising therapeutic targets for potential disease-modifying treatment of Parkinson’s disease. The idea is that pathogenic LRRK2 kinase may alter the dynamics of microtubules and F-actin through abnormal phosphorylation of cytoskeletal proteins leading to defective neurite outgrowth and/or axonal transport1.
LRRK2 kinase assay is run on mobility shift microfluidics platform (Caliper), which provides best in industry quality of data. We routinely run services associated with this kinase including: screening, profiling, dose-response studies and kinetic measurements. Please contact us for more information.
1. Taymans JM, Greggio E. LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson’s Disease, Where Do We Stand?. Current neuropharmacology. 2016 Apr 1;14(3):214-25.
2. Lobbestael E, Civiero L, De Wit T, Taymans JM, Greggio E, Baekelandt V. Pharmacological LRRK2 kinase inhibition induces LRRK2 protein destabilization and proteasomal degradation. Scientific reports. 2016 Sep 23;6:33897.